Cardio-Protective Drug Market
Global Cardio-Protective Drug Market Size, Share & Trends Analysis Report by Treatment (Cholesterol-Lowering, Revascularization, Anti-Inflammatory, and Blood Thinners & Clot Busters), by Type (Antiplatelets, Ace Inhibitors & Arbs, Beta-Blockers, Polypills, and Statins & Others), by Application (Arrhythmia, Coronary Artery Disease, Ischemic Heart Disease, Cardiovascular Disease, Hyperlipidemia, Peripheral Heart Disease, and Hypertension), and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Forecast Period (2022-2028)
The global cardio-protective drug market is anticipated to grow at a significant CAGR of 3.9% during the forecast period. The cardioprotective drug is mainly involved in the prevention of heart and blood vessel blockage which leads to heart attack, chest pain, or other heart problems. Cardio-protection drugs are mainly used before an ischemic event, during an ischemic event, after the event, and during reperfusion. These drugs are important in the treatment of patients at risk for or with documented cardiovascular disease. The rising prevalence of excessive alcohol consumption & smoking leads to different health problems, which is supporting the cardio-protective market over the forecast period. For instance, according to World Health Organization (WHO), as of 2021, tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke.
Impact of COVID-19 Pandemic on Global Cardio-Protective Drug Market
The COVID-19 pandemic had created an unprecedented disruption to global economies and the healthcare industry, with extensive lockdowns and travel bans. Direct viral infection, cytokine storm, and aggravation of existing cardiovascular diseases were recognized as possible mechanisms of cardiovascular impairment in COVID-19. Moreover, hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease, forcing cancer patients to weigh the potential benefit of a face-to-face visit and treatment with the risks of catching the virus.
Segmental Outlook
The global cardio-protective drug market is segmented based on the treatment, type, application, and distribution channel. Based on the treatment, the market is sub-segmented into cholesterol-lowering, revascularization, anti-inflammatory, and blood thinners & clot busters. Based on the type, the market is augmented into antiplatelets, ace inhibitors & arbs, beta-blockers, polypills, and statins & others. Based on the application, the market is again sub-segmented into arrhythmia, coronary artery disease, ischemic heart disease, cardiovascular disease, hyperlipidemia, peripheral heart disease, and hypertension. Based on the distribution channel, the market is further augmented into the hospital pharmacy, online pharmacy, and retail pharmacy. The above-mentioned segments can be customized as per the requirements. Among the type, beta blockers are expected to hold a remarkable share in the market over the forecast period. Beta-blockers are a type of medicine used to treat high blood pressure and heart rhythm disturbances. They are one of several classes of medicines used to treat the heart and related conditions and are also used in the treatment of thyroid disease, migraine, and glaucoma.
Global Cardio-Protective Drug Market Share by Treatment, 2021 (%)
The Cholesterol-Lowering Segment is Expected to Hold a Significant Share in the Global Cardio-Protective Drug Market
Among the treatment segment, the cholesterol-lowering segment is expected to hold a significant share in the market over the forecast period. The rising incidence of high cholesterol among individuals is a serious issue across the globe, which in turn is accelerating the consumption and demand for cholesterol-lowering drugs. Thus, companies are launching new drugs and treatments to control the cholesterol level in individuals to cater to rising demand. For instance, in December 2021, the US FDA approved Novartis’ Leqvio, a small interfering RNA therapy that blocks the translation of the PCSK9 gene. Although the medication must be injected, it is only required to be given twice per year, and it reduces LDL levels by about 52%. Merck & Co.’s MK-0616, a peptide currently in phase 1 clinical trials, can be taken orally, and preliminary data shows that it lowers LDL by 65%.
Regional Outlooks
The global cardio-protective drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. The Europe region is expected to have lucrative growth in this market. This is due to a subsequent rise in the incidence of cardiovascular diseases such as stroke, heart failure, hypertensive heart disease, rheumatic heart disease, and other heart problems.
Global Cardio-Protective Drug Market Growth, by Region 2022-2028
The North America Region is Expected to hold the Considerable Share in the Global Cardio-Protective Drug Market
The North American region is expected to hold a considerable share of the market for cardio-protective drugs. Advancements in pharmaceutical biotechnology in the US for drug development and an increase in the number of cardiovascular patients are the major driving factor in the region. For instance, in May 2020, AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).
Market Players Outlook
The major companies serving the global cardio-protective drug market include Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Siemens Healthineer AG, Takeda Pharmaceuticals Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2021, Merck announced that the U.S. Food and Drug Administration (FDA) approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardio-protective drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1.Report Summary
Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Cardio-Protective Drug Market
Recovery Scenario of Global Cardio-Protective Drug Market
1.1.Research Methods and Tools
1.2.Market Breakdown
1.2.1.By Segments
1.2.2.By Region
2.Market Overview and Insights
2.1.Scope of the Report
2.2.Analyst Insight & Current Market Trends
2.2.1.Key Findings
2.2.2.Recommendations
2.2.3.Conclusion
3.Competitive Landscape
3.1.Key Company Analysis
3.1.1.Overview
3.1.2.Financial Analysis
3.1.3.SWOT Analysis
3.1.4.Recent Developments
3.2.Key Strategy Analysis
3.3.Impact of COVID-19 on Key Players
4.Market Segmentation
4.1.Global Cardio-Protective Drug Market by Treatment
4.1.1.Cholesterol-Lowering
4.1.2.Revascularization
4.1.3.Anti-Inflammatory
4.1.4.Blood Thinners & Clot Busters
4.2.Global Cardio-Protective Drug Market by Type
4.2.1.Antiplatelets
4.2.2.Ace Inhibitors & Arbs
4.2.3.Beta-Blockers
4.2.4.Polypills
4.2.5.Statins & Others
4.3.Global Cardio-Protective Drug Market by Application
4.3.1.Arrhythmia
4.3.2.Coronary Artery Disease
4.3.3.Ischemic Heart Disease
4.3.4.Cardiovascular Disease
4.3.5.Hyperlipidemia
4.3.6.Peripheral Heart Disease
4.3.7.Hypertension
4.4.Global Cardio-Protective Drug Market by Distribution Channel
4.4.1.Hospital Pharmacy
4.4.2.Online Pharmacy
4.4.3.Retail Pharmacy
5.Regional Analysis
5.1.North America
5.1.1.United States
5.1.2.Canada
5.2.Europe
5.2.1.UK
5.2.2.Germany
5.2.3.Italy
5.2.4.Spain
5.2.5.France
5.2.6.Rest of Europe
5.3.Asia-Pacific
5.3.1.China
5.3.2.India
5.3.3.Japan
5.3.4.South Korea
5.3.5.Rest of Asia-Pacific
5.4.Rest of the World
6.Company Profiles
6.1.AstraZeneca Plc
6.2.Amgen Inc.
6.3.Bayer AG
6.4.Boehringer Ingelheim International Gmbh (C.H. Boehringer Sohn AG & Ko. KG)
6.5.Bristol-Myers Squibb Co.
6.6.Daiichi Sankyo Co Ltd.
6.7.Eli Lilly and Co.
6.8.F. Hoffmann-La Roche Ltd.
6.9.Glaxosmithkline Plc
6.10.Gilead Sciences, Inc.
6.11.Johnson & Johnson Services, Inc.
6.12.Merck & Co. Inc.
6.13.Novartis AG
6.14.Nissan Chemical Corp.
6.15.Pfizer Inc.
6.16.Sanofi S.A.
6.17.Siemens Healthineer AG
6.18.Takeda Pharmaceuticals Co. Ltd.
6.19.Tenax Therapeutics Inc.
6.20.Otsuka Holdings Co., Ltd.
1.GLOBAL CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
2.GLOBAL CARDIO-PROTECTIVE DRUG FOR CHOLESTEROL-LOWERING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3.GLOBAL CARDIO-PROTECTIVE DRUG FOR REVASCULARIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4.GLOBAL CARDIO-PROTECTIVE DRUG FOR ANTI-INFLAMMATORY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5.GLOBAL CARDIO-PROTECTIVE DRUG FOR BLOOD THINNERS & CLOT BUSTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6.GLOBAL CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
7.GLOBAL CARDIO-PROTECTIVE DRUG OF ANTIPLATELETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8.GLOBAL CARDIO-PROTECTIVE DRUG OF ACE INHIBITORS & ARBS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9.GLOBAL CARDIO-PROTECTIVE DRUG OF BETA-BLOCKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10.GLOBAL CARDIO-PROTECTIVE DRUG OF POLYPILLS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11.GLOBAL CARDIO-PROTECTIVE DRUG OF STATINS & OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12.GLOBAL CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13.GLOBAL CARDIO-PROTECTIVE DRUG FOR ARRHYTHMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14.GLOBAL CARDIO-PROTECTIVE DRUG FOR CORONARY ARTERY DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15.GLOBAL CARDIO-PROTECTIVE DRUG FOR ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16.GLOBAL CARDIO-PROTECTIVE DRUG FOR CARDIOVASCULAR DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17.GLOBAL CARDIO-PROTECTIVE DRUG FOR HYPERLIPIDAEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18.GLOBAL CARDIO-PROTECTIVE DRUG FOR PERIPHERAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
19.GLOBAL CARDIO-PROTECTIVE DRUG FOR HYPERTENSION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
20.GLOBAL CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
21.GLOBAL CARDIO-PROTECTIVE DRUG IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
22.GLOBAL CARDIO-PROTECTIVE DRUG IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
23.GLOBAL CARDIO-PROTECTIVE DRUG IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
24.GLOBAL CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
25.NORTH AMERICAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26.NORTH AMERICAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
27.NORTH AMERICAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
28.NORTH AMERICAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
29.NORTH AMERICAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
30.EUROPEAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
31.EUROPEAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
32.EUROPEAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
33.EUROPEAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
34.EUROPEAN CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
35.ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
36.ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
37.ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
38.ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
39.ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
40.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
41.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
42.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
43.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
44.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1.IMPACT OF COVID-19 ON GLOBAL CARDIO-PROTECTIVE DRUG MARKET, 2021-2028 ($ MILLION)
2.IMPACT OF COVID-19 ON GLOBAL CARDIO-PROTECTIVE DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3.RECOVERY OF GLOBAL CARDIO-PROTECTIVE DRUG MARKET, 2022-2028 (%)
4.GLOBAL CARDIO-PROTECTIVE DRUG MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
5.GLOBAL CARDIO-PROTECTIVE DRUG FOR CHOLESTEROL-LOWERING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6.GLOBAL CARDIO-PROTECTIVE DRUG FOR REVASCULARIZATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7.GLOBAL CARDIO-PROTECTIVE DRUG FOR ANTI-INFLAMMATORY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8.GLOBAL CARDIO-PROTECTIVE DRUG FOR BLOOD THINNERS & CLOT BUSTERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9.GLOBAL CARDIO-PROTECTIVE DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
10.GLOBAL CARDIO-PROTECTIVE DRUG OF ANTIPLATELETS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11.GLOBAL CARDIO-PROTECTIVE DRUG OF ACE INHIBITORS & ARBS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12.GLOBAL CARDIO-PROTECTIVE OF BETA-BLOCKERS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13.GLOBAL CARDIO-PROTECTIVE DRUG OF POLYPILLS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14.GLOBAL CARDIO-PROTECTIVE DRUG OF STATINS & OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15.GLOBAL CARDIO-PROTECTIVE DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
16.GLOBAL CARDIO-PROTECTIVE DRUG FOR ARRHYTHMIA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17.GLOBAL CARDIO-PROTECTIVE DRUG FOR CORONARY ARTERY DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18.GLOBAL CARDIO-PROTECTIVE DRUG ISCHEMIC HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19.GLOBAL CARDIO-PROTECTIVE DRUG FOR CARDIOVASCULAR DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20.GLOBAL CARDIO-PROTECTIVE DRUG FOR HYPERLIPIDAEMIA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
21.GLOBAL CARDIO-PROTECTIVE DRUG FOR PERIPHERAL HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
22.GLOBAL CARDIO-PROTECTIVE DRUG FOR HYPERTENSION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
23.GLOBAL CARDIO-PROTECTIVE DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
24.GLOBAL CARDIO-PROTECTIVE DRUG IN HOSPITAL PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
25.GLOBAL CARDIO-PROTECTIVE DRUG IN ONLINE PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
26.GLOBAL CARDIO-PROTECTIVE DRUG IN RETAIL PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
27.GLOBAL CARDIO-PROTECTIVE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
28.US CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
29.CANADA CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
30.UK CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
31.FRANCE CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
32.GERMANY CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
33.ITALY CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
34.SPAIN CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
35.REST OF EUROPE CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
36.INDIA CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
37.CHINA CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
38.JAPAN CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
39.SOUTH KOREA CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
40.REST OF ASIA-PACIFIC CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
41.REST OF THE WORLD CARDIO-PROTECTIVE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
